David L. Bartlett specializes in regional therapeutics, the delivery of chemotherapy or biological therapeutic agents directly to the blood vessels leading to a tumor, at the UPMC CancerCenter. Prior to joining University of Pittsburgh Cancer Institute, Dr. Bartlett was a senior investigator in the surgery branch at the Center for Cancer Research at the National Cancer Institute. While serving in this position, he performed isolated limb perfusion for the treatment of melanoma and developed innovative surgical techniques to deliver cancer treatment that resulted in improved survival and quality of life for patients with abdominal and liver cancers.
In addition to his work on regional therapeutics, Dr. Bartlett is investigating tumor-directed gene therapy for cancer. He is currently working with the vaccinia virus (smallpox vaccine virus), using it as a vector to deliver gene therapy directly to tumor sites, and genetically engineering the virus to kill cancer cells.
Dr. Bartlett received his medical degree from the University of Texas Medical School at Houston and completed his surgical training at the Hospital of the University of Pennsylvania in Philadelphia. He also completed a fellowship in surgical oncology at Memorial Sloan-Kettering Cancer Center in New York.
Among his accomplishments, Dr. Bartlett has authored numerous articles on regional treatment strategies and tumor-directed gene therapy in peer-reviewed journals such as Cancer Research and the Journal of the National Cancer Institute. He has also authored several chapters in textbooks on cancer therapeutics and surgical oncology.
Dr. Lanie Francis is a medical oncologist and hematologist at the Hillman Cancer Center, the flagship of UPMC CancerCenter. She sees patients with a broad array of solid tumors including, but not limited to, breast cancer, GI cancer, and brain tumors. In addition, she sees a broad array of hematologic issues including leukemias, lymphomas, blood clots and anemia with a particular interest in pregnant women with hematologic disease.
She is presently the Principal Investigator for a phase III supportive care trial investigating a novel approach to managing nausea and a sub-investigator on a variety of other clinical research studies at University of Pittsburgh Cancer Institute (UPCI).
Dr. Francis directs the Integrative Oncology at UPMC CancerCenter. This is a comprehensive consult service and program for oncology patients that addresses the body, mind and spirit within the context of standard oncology treatment. The goal is to treat symptoms and improve quality of life through movement, touch, nutrition and mindfulness.
Dr. Francis received an undergraduate degree from Brown University in Providence, R.I. and earned her medical degree at the University of Pittsburgh School of Medicine. Dr. Francis completed a residency in internal medicine at George Washington University Medical Center in Washington, DC., and a fellowship in hematology and oncology at the University of Pittsburgh School of Medicine. Dr. Francis is a member of professional organizations such as the American Society of Hematology, American Society of Clinical Oncology, Allegheny County Medical Society, and the society of Integrative Oncology.
Dr. Francis is the author of several publications in peer-reviewed journals. She writes and lectures on lifestyle and cancer.
Bruno Gridelli is a transplant surgeon and the Medical & Scientific Director of University of Pittsburgh Medical Center (UPMC) International. Since 2003 Dr. Gridelli has served as Director of the Mediterranean Institute of Transplantation and Advanced Therapies - ISMETT (IStituto MEditerraneo per i Trapianti e Terapie ad Alta Specializzazione: www.ismett.edu) in Palermo, Italy, a public hospital created by a public-private partnership between the Region of Sicily and UPMC.
Under Dr. Gridelli’s direction the Institute has earned national and international accreditations (JCI- Joint Commission International) and awards (Public Administration forum and HIMSS level 6), which testify to the excellence in the quality and safety of care, transparency and efficiency in the use of resources and level of digitalization recognized as amongst the highest in the world. In January 2009 he assumed responsibility for the Legal Representation of the Institute and was appointed Director and CEO of ISMETT.
Under Dr. Gridelli’s direction ISMETT has increased its liver and kidney transplant activity and undertaken a variety of new clinical programs such as heart, lung, pancreas and islet cell transplantation. ISMETT has performed more living-donor liver transplants than any center in Italy. ISMETT has performed over 1,500 transplants and has one of the most active ventricular assist device (VAD) programs in Italy
Dr. Gridelli spearheaded the creation of the Ri.MED Foundation (www.fondazionerimed.com), and assumed the Vice- Presidency in 2006. The Ri.MED Foundation is an international partnership of the Italian Government, the Region of Sicily, the Italian National Research Center (CNR), the University of Pittsburgh, and the University of Pittsburgh Medical Center with the mission of promoting and supporting biomedical and biotechnology research and development. The Foundation received €290 million from the Italian government to pursue its objectives. The Foundation’s principal project is the creation of a Biomedical Research and Biotechnology Center (BRBC) in Carini, near Palermo, a 31.000 square meter facility, that will house eight advanced and highly competitive research programs, and employ over 600 scientists and technicians.
In December 2007, Dr. Gridelli was appointed Medical & Scientific Director of UPMC International. In this position he directs clinical and scientific activity for all international locations, thus contributing to the development of a network of collaborations and partnerships in Ireland, United Kingdom, Italy, Qatar, Singapore, China and Kazakhstan. In his role as International Medical & Scientific Director, Dr. Gridelli works to transfer UPMC-”Best Clinical and Managerial Practices” around the world.
Dwight E. Heron currently serves as the vice chairman of Clinical Affairs at UMPC Shadyside, professor of Radiation Oncology, Otolaryngology and Head and Neck Surgery at the University of Pittsburgh School of Medicine, director of Radiation Services the at UPMC CancerCenter, and chairman of the department of Radiation Oncology at UPMC Shadyside.
Dr. Heron specializes in stereotactic radiosurgery, high-dose rate brachytherapy, and intensity modulated radiation therapy (IMRT). His research interests include stereotactic radiotherapy for benign and malignant brain and body tumors; evaluation of PET/CT in staging and management of head and neck, lung, and a variety of other cancers—including the use of 4D PET-CT for thoracic and abdominal malignancies; and the identification and management of factors contributing to differences in cancer care in various populations in Western Pennsylvania.
Dr. Heron came to the University of Pittsburgh from Thomas Jefferson University where he completed his residency in radiation oncology following an internal medicine internship at Winthrop University Hospital in Mineola, NY. He is a graduate of Fairfield University and received his medical degree from the University of Rochester School of Medicine and Dentistry. He is a member of several professional associations including the American Brachytherapy Society, the American College of Radiation Oncology, and the American College of Radiology.
Margarita Zuley is an Associate Professor of Radiology at the University of Pittsburgh School of Medicine and also serves as the Medical Director of Breast Imaging at Magee-Womens Hospital of UPMC. Dr. Zuley also serves as Director of Breast Imaging Quality for the University of Pittsburgh Medical Center.
Dr. Zuley is board certified in Radiology. She earned her BS degree from the University of Notre Dame where she graduated cum laude. She received her medical degree from the University of Pittsburgh Medical Center. She completed her Residency program at the University of Pittsburgh during which time she served as Chief Resident. After residency, she was accepted into the University of Pittsburgh, Department of Radiology this time as a Fellow in Women’s Imaging.
As the Medical Director of Breast Imaging, at Magee-Womens Hospital of UPMC Dr. Zuley is responsible for providing strategies and policies for the day-to-day operation of a busy Breast Imaging Division, performing over 150,000 mammographic procedures annually at several locations. Keeping the department on the cutting edge of technology, she introduced the novel procedure of radioactive seed localization to the clinical team at Magee and it was rapidly implemented now, largely replacing wire localization. After actively participating in research in tomosynthesis since 2007 she implemented screening and diagnostic tomosynthesis clinical programs once the technology received FDA approval in 2011. In addition she started a screening ultrasound program for patients with dense breast tissue.
Dr. Zuley’s active areas of research currently include new technology evaluation including digital breast tomosynthesis, painless mammography and Cone Beam CT. She is currently the principal investigator on grants from the NIH, and from Industry to investigate these new technologies. She has many peer reviewed publications as a result of her research and is a sought after speaker. In addition, she has received several awards, including divisional teacher of the year several times from the radiology residents, the ACES award from UPMC for outstanding service and has been an honored faculty at the University of Pittsburgh.
Dr. Zuley is a member of several professional organizations including the American Medical Association, American College of Radiology, American Roentgen Ray Society, Radiologic Society of North America, and the Society of Breast Imaging. She is a fellow of the Society of Breast Imaging and serves as a grant reviewer for the NIH, a consultant to the Food and Drug Administration Medical Device Committee and is a member of several national committees.